Active, not recruitingPHASE1, PHASE2NCT07197268
Personalized Antisense Oligonucleotide Therapy for A Single Participant With ASXL3 Gene Mutation
Studying Bainbridge-Ropers syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- n-Lorem Foundation
- Intervention
- nL-ASXL3-001(drug)
- Enrollment
- 1 enrolled
- Eligibility
- 4-4 years · MALE
- Timeline
- 2025 – 2027
Study locations (1)
- University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States
Collaborators
University of North Carolina, Chapel Hill
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07197268 on ClinicalTrials.govOther trials for Bainbridge-Ropers syndrome
Additional recruiting or active studies for the same condition.